AIMS: Recent-onset dilated cardiomyopathy (RODCM) is characterized by heterogeneous aetiology and diverse clinical outcomes, with scarce data on genotype-phenotype correlates. Our aim was to correlate individual RODCM genotypes with left ventricular reverse remodelling (LVRR) and clinical outcomes. METHODS AND RESULTS: In this prospective study, a total of 386 Czech RODCM patients with symptom duration ≤6 months underwent genetic counselling and whole-exome sequencing (WES). The presence of pathogenic (class 5) or likely pathogenic (class 4) variants in a set of 72 cardiomyopathy-related genes was correlated with the occurrence of all-cause death, heart transplantation, or implantation of a ventricular assist device (primary outcome) and/or ventricular arrhythmia event (secondary outcome). LVRR was defined as an improvement of left ventricular ejection fraction to >50% or ≥10% absolute increase, with a left ventricular end-diastolic diameter ≤33 mm/m2 or ≥10% relative decrease. Median follow-up was 41 months. RODCM was familial in 98 (25%) individuals. Class 4-5 variants of interest (VOIs) were identified in 125 (32%) cases, with 69 (18%) having a single titin-truncating variant (TTNtv) and 56 (14%) having non-titin (non-TTN) VOIs. The presence of class 4-5 non-TTN VOIs, but not of TTNtv, heralded a lower probability of 12-month LVRR and proved to be an independent baseline predictor both of the primary and the secondary outcome. The negative result of genetic testing was a strong protective baseline variable against occurrence of life-threatening ventricular arrhythmias. Detection of class 4-5 VOIs in genes coding nuclear envelope proteins was another independent predictor of both study outcomes at baseline and also of life-threatening ventricular arrhythmias after 12 months. Class 4-5 VOIs of genes coding cytoskeleton were associated with an increased risk of life-threatening ventricular arrhythmias after baseline assessment. A positive family history of dilated cardiomyopathy alone only related to a lower probability of LVRR at 12 months and at the final follow-up. CONCLUSIONS: RODCM patients harbouring class 4-5 non-TTN VOIs are at higher risk of progressive heart failure and life-threatening ventricular arrhythmias. Genotyping may improve their early risk stratification at baseline assessment.

1st Internal Clinic of Cardio Angiology St Anne's University Hospital and Medical School of Masaryk University Brno Czech Republic

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiovascular Medicine 2nd Department of Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Internal Medicine 1 Cardiology University Hospital Olomouc Olomouc Czech Republic

Department of Pathological Physiology Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

Department of Pediatrics and Adolescent Medicine 1st Faculty of Medicine Research Unit for Rare Diseases Charles University Prague Czech Republic

European Reference Network for Rare Low Prevalence and Complex Diseases of the Heart ERN GUARD Heart IKEM Prague Czech Republic

Institute of Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, PubMed DOI

Merlo M, Pyxaras SA, Pinamonti B, Barbati G, di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 2011;57:1468‐1476. doi: 10.1016/j.jacc.2010.11.030 PubMed DOI

Givertz MM, Mann DL. Epidemiology and natural history of recovery of left ventricular function in recent onset dilated cardiomyopathies. Curr Heart Fail Rep 2013;10:321‐330. doi: 10.1007/s11897-013-0157-5 PubMed DOI PMC

Kubanek M, Sramko M, Maluskova J, Kautznerova D, Weichet J, Lupinek P, PubMed DOI

Spezzacatene A, Sinagra G, Merlo M, Barbati G, Graw SL, Brun F, PubMed DOI PMC

Kayvanpour E, Sedaghat‐Hamedani F, Amr A, Lai A, Haas J, Holzer DB, PubMed DOI

Peters S, Kumar S, Elliott P, Kalman JM, Fatkin D. Arrhythmic genotypes in familial dilated cardiomyopathy: Implications for genetic testing and clinical management. Heart Lung Circ 2019;28:31‐38. doi: 10.1016/j.hlc.2018.09.010 PubMed DOI

Taylor MR, Fain PR, Sinagra G, Robinson ML, Robertson AD, Carniel E, PubMed DOI

Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF, PubMed DOI

van Rijsingen IA, van der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JD, Zwinderman AH, PubMed DOI

Ortiz‐Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado‐Aranda R, Climent V, PubMed DOI

Begay RL, Graw SL, Sinagra G, Asimaki A, Rowland TJ, Slavov DB, PubMed DOI PMC

Parikh VN, Caleshu C, Reuter C, Lazzeroni LC, Ingles J, Garcia J, PubMed DOI PMC

Domínguez F, Cuenca S, Bilińska Z, Toro R, Villard E, Barriales‐Villa R, PubMed DOI PMC

Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: The complexity of a diverse genetic architecture. Nat Rev Cardiol 2013;10:531‐547. doi: 10.1038/nrcardio.2013.105 PubMed DOI

Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, PubMed DOI

McNally EM, Mestroni L. Dilated cardiomyopathy: Genetic determinants and mechanisms. Circ Res 2017;121:731‐748. doi: 10.1161/CIRCRESAHA.116.309396 PubMed DOI PMC

Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, PubMed DOI PMC

van Spaendonck‐Zwarts KY, van Rijsingen IA, van den Berg MP, Lekanne Deprez RH, Post JG, van Mil AM, PubMed DOI

Jansweijer JA, Nieuwhof K, Russo F, Hoorntje ET, Jongbloed JD, Lekanne Deprez RH, PubMed DOI

Tobita T, Nomura S, Fujita T, Morita H, Asano Y, Onoue K, PubMed DOI PMC

Gigli M, Merlo M, Graw SL, Barbati G, Rowland TJ, Slavov DB, PubMed DOI PMC

Verdonschot JAJ, Hazebroek MR, Wang P, Sanders‐van Wijk S, Merken JJ, Adriaansen YA, PubMed DOI

Escobar‐Lopez L, Ochoa JP, Mirelis JG, Espinosa MÁ, Navarro M, Gallego‐Delgado M, PubMed DOI

Silverdal J, Sjöland H, Pivodic A, Dahlström U, Fu M, Bollano E. Prognostic differences in long‐standing vs. recent‐onset dilated cardiomyopathy. ESC Heart Fail 2022;9:1294‐1303. doi: 10.1002/ehf2.13816 PubMed DOI PMC

Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, PubMed DOI

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, PubMed DOI

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, PubMed DOI

Quinones MA, Otto CM, Stoddard W, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography. J Am Soc Echocardiogr 2002;15:167‐184. doi: 10.1067/mje.2002.120202 PubMed DOI

Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, PubMed DOI

Richards S, Aziz N, Bale S, Bick D, das S, Gastier‐Foster J, PubMed DOI PMC

Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E, PubMed DOI PMC

Owens AT, Day SM. Reappraising genes for dilated cardiomyopathy: Stepping Back to move forward. Circulation 2021;144:20‐22. doi: 10.1161/CIRCULATIONAHA.121.054961 PubMed DOI

https://gnomad.broadinstitute.org/. Accessed January 2015 to June 2020.

Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, PubMed DOI PMC

Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno‐Blanes J, PubMed DOI

Corden B, Jarman J, Whiffin N, Tayal U, Buchan R, Sehmi J, PubMed DOI PMC

Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, PubMed DOI

Zeppenfeld K, Tfelt‐Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, PubMed DOI

Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales‐Villa R, Basso C, PubMed DOI